Chongqing Tan

1.3k total citations
65 papers, 978 citations indexed

About

Chongqing Tan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Chongqing Tan has authored 65 papers receiving a total of 978 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in Chongqing Tan's work include Cancer Immunotherapy and Biomarkers (18 papers), Economic and Financial Impacts of Cancer (15 papers) and Lung Cancer Treatments and Mutations (14 papers). Chongqing Tan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (18 papers), Economic and Financial Impacts of Cancer (15 papers) and Lung Cancer Treatments and Mutations (14 papers). Chongqing Tan collaborates with scholars based in China, Australia and United Kingdom. Chongqing Tan's co-authors include Xiaohui Zeng, Xiaomin Wan, Liubao Peng, Xia Luo, Yucong Zhang, Lidan Yi, Qiao Liu, Jianhe Li, Sini Li and Peng Ye and has published in prestigious journals such as PLoS ONE, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Chongqing Tan

63 papers receiving 969 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chongqing Tan China 18 632 541 241 203 104 65 978
Xiaomin Wan China 17 553 0.9× 511 0.9× 247 1.0× 188 0.9× 90 0.9× 71 1.0k
Liubao Peng China 14 471 0.7× 432 0.8× 195 0.8× 141 0.7× 73 0.7× 48 760
Cristina Ivanescu United States 14 370 0.6× 659 1.2× 89 0.4× 152 0.7× 184 1.8× 71 1.0k
Laura Marandino Italy 19 477 0.8× 360 0.7× 69 0.3× 509 2.5× 99 1.0× 95 1.1k
Mihaela Mates Canada 15 572 0.9× 188 0.3× 58 0.2× 88 0.4× 179 1.7× 50 837
María T. Bourlon Mexico 15 417 0.7× 590 1.1× 47 0.2× 216 1.1× 213 2.0× 81 835
Sabeen Mekan United States 14 479 0.8× 439 0.8× 44 0.2× 102 0.5× 146 1.4× 52 838
Christian Lerchenmüller Germany 16 582 0.9× 417 0.8× 38 0.2× 135 0.7× 164 1.6× 49 890
Daniele Lisi Italy 7 559 0.9× 303 0.6× 56 0.2× 274 1.3× 106 1.0× 10 1.0k

Countries citing papers authored by Chongqing Tan

Since Specialization
Citations

This map shows the geographic impact of Chongqing Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chongqing Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chongqing Tan more than expected).

Fields of papers citing papers by Chongqing Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chongqing Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chongqing Tan. The network helps show where Chongqing Tan may publish in the future.

Co-authorship network of co-authors of Chongqing Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Chongqing Tan. A scholar is included among the top collaborators of Chongqing Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chongqing Tan. Chongqing Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Siying, et al.. (2024). Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma. Expert Review of Pharmacoeconomics & Outcomes Research. 25(2). 173–178. 2 indexed citations
2.
Ma, Jing, Sini Li, Chongqing Tan, et al.. (2024). Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study. PharmacoEconomics. 42(12). 1345–1357. 1 indexed citations
3.
Li, Andong, et al.. (2024). Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States. Frontiers in Immunology. 15. 1464092–1464092. 4 indexed citations
4.
Wu, Mei-Yu, et al.. (2024). Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial. Expert Review of Pharmacoeconomics & Outcomes Research. 24(8). 1043–1051. 1 indexed citations
5.
6.
7.
Ye, Peng, Liting Wang, Liubao Peng, et al.. (2023). Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States. Clinical Therapeutics. 45(10). 965–972. 3 indexed citations
8.
9.
Liu, Qiao, Xia Luo, Zhen Zhou, et al.. (2021). PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC： A Cost-Effectiveness Analysis in China. Frontiers in Oncology. 11. 745493–745493. 3 indexed citations
10.
Li, Sini, Jianhe Li, Liubao Peng, et al.. (2021). First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis. Clinical Therapeutics. 43(7). 1253–1264.e5. 3 indexed citations
11.
Yi, Lidan, Sini Li, Chongqing Tan, et al.. (2021). Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer. Advances in Therapy. 38(6). 3399–3408. 11 indexed citations
12.
Ye, Peng, Xiaohui Zeng, Liubao Peng, et al.. (2021). Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer. Advances in Therapy. 38(7). 3962–3972. 12 indexed citations
13.
Li, Sini, Liubao Peng, Chongqing Tan, et al.. (2020). Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China. PLoS ONE. 15(5). e0232240–e0232240. 22 indexed citations
14.
Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2020). Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open. 10(11). e040691–e040691. 8 indexed citations
15.
16.
Zeng, Xiaohui, Xiaomin Wan, Liubao Peng, et al.. (2019). Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA. BMJ Open. 9(12). e031019–e031019. 17 indexed citations
17.
Ye, Peng, Chongqing Tan, Xiaomin Wan, et al.. (2019). Model-Based Economic Evaluation of Ceritinib and Platinum-Based Chemotherapy as First-Line Treatments for Advanced Non-Small Cell Lung Cancer in China. Advances in Therapy. 36(11). 3047–3058. 6 indexed citations
18.
Liu, Qiao, Xia Luo, Liubao Peng, et al.. (2019). Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis. Clinical Drug Investigation. 40(2). 129–137. 40 indexed citations
19.
Chen, Jun, Gaoyun Hu, Zhuo Chen, et al.. (2019). Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China. Clinical Drug Investigation. 39(10). 931–938. 28 indexed citations
20.
Zeng, Xiaohui, Jianhe Li, Liubao Peng, et al.. (2014). Economic Outcomes of Maintenance Gefitinib for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer with Unknown EGFR Mutations: A Semi-Markov Model Analysis. PLoS ONE. 9(2). e88881–e88881. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xiaomin Wan Breakdown of academic impact, for papers by Liubao Peng Breakdown of academic impact, for papers by Cristina Ivanescu Breakdown of academic impact, for papers by Laura Marandino Breakdown of academic impact, for papers by Mihaela Mates Breakdown of academic impact, for papers by María T. Bourlon Breakdown of academic impact, for papers by Sabeen Mekan Breakdown of academic impact, for papers by Christian Lerchenmüller Breakdown of academic impact, for papers by Daniele Lisi
Rankless by CCL
2026